ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2022

Abstract Number: 0695

Epidemiology of Behçet’s Disease in Northern Spain

Carmen Alvarez Reguera1, guillermo Suárez-Amorin1, Rosalía Demetrio-Pablo1, Raúl fernández-ramón1, Alba Herrero-Morant2, Lara Sánchez-Bilbao1, David Martínez-López1, José Luis Martín-Varillas3, Santos Castañeda4, Miguel Ángel González-Gay5 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital de Laredo, Laredo, Cantabria, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, Epidemiology

Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The prevalence of Behçet’s disease (BD) has a considerable geographical and temporal variability. Data regarding epidemiology in Spain are limited. Our study aimed to assess the epidemiology and clinical domains of BD in a population-based cohort from northern Spain and to compare the results with other geographical areas.

Methods: We conducted a cross-sectional study of a well-defined population in Northern Spain. Cases of suspected BD between January 1980 and December 2018 were identified. The diagnosis of BD was established according to the International Study Group (ISG) for Behçet’s Disease. The incidence of BD between 1999 and 2018 was estimated by sex, age, and year of diagnosis.

Results: Of 120 patients with probable BD, 59 patients met ISG criteria and were finally included in the study, with a male/female ratio of 0.97; mean age 49.7±14.7 years. Incidence during the period of study was 0.492 per 100,000 people, observing an increase from January 1999 to December 2018. Prevalence was 10.14 per 100,000 in 2018. Clinical manifestations were relapsing aphthous stomatitis (100%), genital ulcers (78%), skin involvement (84.7%), joint involvement (64.4%), uveitis (55.9%), central nervous system (16.9%), vascular (10.2%), and gastrointestinal manifestations (6.8%).

Conclusion: The prevalence of BD in Cantabria is higher than in other Southern-European countries. This difference may reflect a combination of geographic, genetic, or methodological variations, as well as the free accessibility to the Spanish Public Health System. Clinical phenotypes observed are similar to those described in other world regions.

Supporting image 1

Abbreviations: ISG: International Study Group; ICBD: International Criteria for Behçet’s Disease; NR: Not Reported; SD: Standard Deviation.

Supporting image 2


Disclosures: C. Alvarez Reguera, None; g. Suárez-Amorin, None; R. Demetrio-Pablo, None; R. fernández-ramón, None; A. Herrero-Morant, None; L. Sánchez-Bilbao, Eli Lilly; D. Martínez-López, None; J. Martín-Varillas, AbbVie/Abbott, Pfizer, Janssen, UCB, Celgene; S. Castañeda, Roche; M. González-Gay, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Roche, Sanofi, Eli Lilly, Celgene, Sobi, Merck/MSD; R. Blanco, Eli Lilly, Pfizer, Roche, Janssen, MSD, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galapagos, Novartis, Sanofi.

To cite this abstract in AMA style:

Alvarez Reguera C, Suárez-Amorin g, Demetrio-Pablo R, fernández-ramón R, Herrero-Morant A, Sánchez-Bilbao L, Martínez-López D, Martín-Varillas J, Castañeda S, González-Gay M, Blanco R. Epidemiology of Behçet’s Disease in Northern Spain [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/epidemiology-of-behcets-disease-in-northern-spain/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-of-behcets-disease-in-northern-spain/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology